Envelope Protein/E Protein (DENV)

Dengue is a mosquito-borne viral disease widely spread all over the world transmitted by 4 serotypes of dengue virus (DENV). The symptoms range from mild dengue fever to dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) with high mortality. Currently, most of the studies on DENV vaccines emphasize on its envelope protein which is essential for viral attachment and fusion (i.e., Sanofi’s tetravalent dengue vaccine Dengvaxia). However, the vaccine of envelope protein still needs to be improved to maximize its efficiency on people never infected with DENV before, which requires more research to be conducted on the DENV envelope protein.